FTC Requires Divestitures of Generic Drugs in Acquisition of CorePharma by Impax Labs


Raymond Jacobson was noted as counsel to Impax Laboratories in a proposed FTC settlement that would resolve projected anticompetitive consequences in the $700 million consolidation of CorePharma LLC into Impax by requiring the parties to divest all rights and assets to two generic drugs.